Amentoflavone

CYP3A4 Inhibition — The Mechanism That Actually Matters#

The single most pharmacologically relevant action of amentoflavone in a supplement context is potent inhibition of cytochrome P450 3A4, the enzyme responsible for first-pass and systemic metabolism of roughly half of all orally administered drugs — including caffeine's downstream metabolites, yohimbine, synephrine, tadalafil, sildenafil, and many orals. Wang et al. (2022) characterized this inhibition at sub-micromolar potency, placing amentoflavone among the strongest naturally occurring CYP3A4 inhibitors identified.

"Amentoflavone exhibited marked inhibition of CYP3A4 with an IC50 of 0.37 μM, indicating significant potential to alter the metabolism of co-administered drugs." — Wang B, Shi C, Feng L, et al. Frontiers in Pharmacology, 2022

Practical consequence: this is why amentoflavone appears in stimulant fat-burners and potentiator stacks. When co-ingested with a thermogenic, it blunts first-pass clearance, flattening and extending the stim curve rather than raising the peak. It is — mechanistically — the grapefruit-juice effect in capsule form. This is also why the side-effect profile lives almost entirely in drug interactions rather than in the molecule's own toxicity.

Benzodiazepine Site Affinity at GABAA#

Amentoflavone binds the central benzodiazepine allosteric site on the GABAA receptor with nanomolar affinity, sitting alongside flavones like apigenin in a small group of plant-derived positive allosteric modulators with real pharmacological relevance at that target.

"Amentoflavone displayed a high affinity (Ki = 15 nM) for the central benzodiazepine binding site, a value among the highest reported for plant-derived ligands." — Nielsen M, Frøkjaer S, Braestrup C. Biochemical Pharmacology, 1988

Practical consequence: this is the mechanistic basis for evening GABAergic sleep stacks pairing amentoflavone with apigenin, magnesium glycinate, or glycine. The effect is best characterized as an "edge off" — a partial anxiolytic nudge, not a hypnotic knockout. It also explains why late-day dosing alongside a stimulant-paired fat-burner stacks poorly with sleep quality: the GABA-site nudge is overwhelmed by the extended stim half-life that amentoflavone itself is creating upstream.

Pancreatic Lipase and Fatty Acid Synthase Inhibition#

Biflavones from Ginkgo biloba, with amentoflavone as an active constituent, directly inhibit pancreatic lipase at the gut lumen — reducing dietary triglyceride hydrolysis and absorption — and inhibit fatty acid synthase (FAS) in peripheral tissue in vitro. Because oral bioavailability of the free molecule is under 1% (see pharmacokinetics section), the gut-lumen lipase action is the mechanistically credible half of this story. Peripheral FAS inhibition requires systemic exposure that plain capsule powder does not deliver.

Practical consequence: a modest adjunct role during a cut, dosed with fat-containing meals, at the 100–200 mg tier. This is a tertiary mechanism — not a primary fat-loss driver, and anyone framing amentoflavone as a standalone thermogenic is overselling it.

PPAR-γ and C/EBPα Suppression in Adipocyte Differentiation#

In 3T3-L1 adipocyte models, amentoflavone suppresses the master adipogenic transcription factors PPAR-γ and C/EBPα, blunting pre-adipocyte differentiation into mature fat cells.

"Amentoflavone was shown to inhibit adipocyte differentiation via PPAR-γ and C/EBPα suppression, supporting an anti-adipogenic effect in vitro." — Yadav N, et al. Pharmacological Research, 2021

Practical consequence: theoretically relevant to long-term body-composition maintenance rather than acute fat loss, and the in vivo translation at oral supplement doses is unproven. Treat this as mechanism-interesting, outcome-uncertain — the scalar fat-loss score of 2 reflects exactly that gap.

Aromatase — Effectively Inert#

Amentoflavone is a biflavonoid of apigenin, and apigenin is a real (if weak) aromatase inhibitor. The intuitive extrapolation — that the dimer would inherit or amplify the activity — is the pitch used in "natural PCT" and on-cycle estrogen-control blends. The data do not support it.

"Amentoflavone displayed only a physiologically irrelevant, slight aromatase inhibition and did not exert ER-mediated estrogenic activity." — Dilek E, et al. Life Sciences, 2021

Practical consequence: do not rely on amentoflavone for estrogen management on a real AAS cycle. A proper aromatase inhibitor (anastrozole, exemestane) is the correct tool. If amentoflavone contributes anything to those blends, it is via CYP3A4-mediated alteration of the other botanicals' exposure, not direct steroid-axis action.

Bioavailability — The Mechanism Ceiling#

Every systemic mechanism above runs into the same wall: oral absorption of the free molecule is essentially negligible, and conjugated metabolites dominate whatever plasma signal exists.

"The oral bioavailability of amentoflavone was 0.04% for the free compound and 0.16% for total conjugates, highlighting extensive first-pass metabolism." — Chen F, et al. Journal of Agricultural and Food Chemistry, 2014

Practical consequence: the gut-level mechanisms (pancreatic lipase inhibition, first-pass CYP3A4 blockade of co-ingested actives) are pharmacologically plausible at real supplement doses because they do not require systemic exposure. The systemic-target claims (peripheral PPAR-γ, FAS in adipocytes, aromatase) need a solubilized or phospholipid-complexed preparation to be taken seriously. Formulation matters more than raw milligrams — a 50 mg phytosome dose is not the same molecule-in-blood as a 50 mg raw-powder capsule.

Common (most users)#

• Mild GI upset / loose stools — consistent with pancreatic lipase inhibition at the gut lumen. Dose with food, split across two servings, or drop to 50mg if it persists. Usually resolves within the first week.
• Drowsiness or "edge-off" sedation — expected from the BZD-site affinity documented in Nielsen 1988. If daytime dosing is sedating, shift the full dose to evening. Pairs well with a sleep stack; pairs poorly with early-shift work.
• Stim potentiation feeling "too much" — the whole point of the molecule in a fat-burner context is extending stimulant AUC via CYP3A4 blockade. When caffeine or yohimbine hit harder and linger longer than expected, cut the stim dose first, not the amentoflavone.
• Late-day stim overhang — same mechanism, evening version. Front-load the dose with the morning stimulant; never repeat after ~2pm when stacked with caffeine or ephedrine analogs.
• Mild headache — typically resolves with hydration and taking the dose with a meal.

Uncommon (dose-dependent or individual)#

• Exaggerated response to a prescription medication — the single most common "weird" reaction, and it is not really a side effect of amentoflavone itself but of everything else in the medicine cabinet. Statins, macrolides, tadalafil, sildenafil, alprazolam, and dozens of other CYP3A4 substrates see elevated AUC (Wang 2022, IC50 0.37 μM). Review the medication list and treat the supplement like grapefruit juice.

"Amentoflavone exhibited marked inhibition of CYP3A4 with an IC50 of 0.37 μM, indicating significant potential to alter the metabolism of co-administered drugs." — Wang et al., Frontiers in Pharmacology (2022)

• Additive sedation with other GABAergic agents — kava, apigenin, magnolia bark, phenibut, alcohol. Stacking multiple BZD-site ligands compounds sedation unpredictably. Run one GABAergic adjunct at a time and titrate.
• Potentiation of anticoagulants — CYP2C9 inhibition extends warfarin and some NSAID exposure. Subjects on chronic anticoagulation should avoid the molecule entirely rather than try to dose around it.
• Elevated exposure to metformin or cimetidine — MATE1 transporter inhibition (Duan 2024) can raise plasma levels of renally secreted cationic drugs. Relevant for anyone running metformin as a recomp tool.
• Dose-plateau with no added benefit above ~100mg — oral bioavailability of the free molecule is sub-1% (Chen 2014). Pushing past 100mg raw powder rarely produces more effect; a smaller dose in a phospholipid or cyclodextrin formulation outperforms a larger dose of plain powder.

Rare but serious#

• Clinically meaningful drug interaction with a narrow-therapeutic-index substrate — tacrolimus, cyclosporine, certain antiarrhythmics, and some antiretrovirals sit in a range where a 30–50% AUC increase matters. Stop immediately if unexplained symptoms emerge in anyone on these medications.
• Serotonin-syndrome–adjacent presentations when stacked with St. John's Wort extracts — the botanical source itself contains amentoflavone plus hyperforin plus SSRI-like constituents. Isolated amentoflavone does not drive this, but mixing concentrates with the parent extract can.
• Hepatic enzyme elevation — not directly reported for isolated amentoflavone, but plausible when stacked with hepatotoxic orals whose clearance is CYP3A4-dependent. Standard on-cycle LFTs catch this.
• Bleeding events — theoretical via CYP2C9 inhibition in subjects on anticoagulants or high-dose fish oil / aspirin stacks. Bruising, prolonged bleeding from minor cuts, or epistaxis warrants discontinuation.

Hard contraindications#

• Narrow-therapeutic-index CYP3A4 substrates — tacrolimus, cyclosporine, certain antiarrhythmics (amiodarone, quinidine), and select antiretroviral regimens. Do not stack.
• Warfarin or other CYP2C9-sensitive anticoagulants — bleeding risk from elevated AUC. Not an appropriate adjunct.
• Concurrent prescription benzodiazepines — additive BZD-site activity plus CYP3A4-mediated AUC increase of the BZD itself. Two mechanisms stacked on top of each other; avoid.
• Pregnancy and lactation — no human safety data for isolated amentoflavone. Default exclusion.
• Subjects taking any medication with a known grapefruit-juice warning — that warning is functionally a CYP3A4-inhibition warning. The same logic applies here.

Sex-specific and cycle considerations#

Non-hormonal, non-aromatase-relevant. Dilek et al. (2021) demonstrated that amentoflavone produces only a "physiologically irrelevant" aromatase inhibition with no ER-mediated estrogenic activity, so there is no virilization concern for female subjects and no estrogen-axis rationale for on-cycle male protocols. Dosing is not bodyweight-adjusted and does not need to differ across the subject pool.

No HPTA suppression, no PCT required. The molecule can be included in a natural "on-cycle support" blend without consequence to the hormonal recovery arc — but the estrogen-management claims attached to those blends are not supported by the data on this molecule specifically. Subjects running real AAS cycles should pair with an actual aromatase inhibitor (anastrozole, exemestane) rather than leaning on biflavone blends for estrogen control.